dc.creator | Martínez-Chinchilla, Carlos | es |
dc.creator | Vazquez Montero, Lucía | es |
dc.creator | Palazón Carrión, Natalia | es |
dc.creator | Fernández Román, Isabel M. | es |
dc.creator | López Barba, José | es |
dc.creator | Cruz Merino, Luis de la | es |
dc.creator | Rodríguez-Baño, Jesús | es |
dc.creator | Palacios-Baena, Zaira R. | es |
dc.date.accessioned | 2022-11-22T15:26:47Z | |
dc.date.available | 2022-11-22T15:26:47Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Martínez-Chinchilla, C., Vazquez Montero, L., Palazón-Carrión, N., Fernández Román, I.M., López Barba, J., Cruz Merino, L.d.l.,...,Palacios-Baena, Z.R. (2022). Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Patients With Complete Remission B-Cell Lymphoma and Anti-CD20 Monoclonal Antibody Therapy: A Case Report of Two Cases. Frontiers in Immunology, 13, 1-7. https://doi.org/10.3389/fimmu.2022.860891. | |
dc.identifier.issn | 1664-3224 | es |
dc.identifier.uri | https://hdl.handle.net/11441/139686 | |
dc.description.abstract | Immunosuppressant conditions such as hematological malignancies increase the risk of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. It has been
described in the literature that patients on anti-CD20 maintenance therapies for lymphoid
malignancies are susceptible to having recurrent flares together with viral replication or
reinfections, although these cases are scarce. These patients are not well represented in
randomized controlled trials, and as a consequence, the evidence for the use of certain
treatments in this scenario is lacking. We present two cases of patients with B-cell
lymphoma on remission and treated with rituximab on maintenance. They developed at
least 1 flare of coronavirus disease 2019 (COVID-19) after acute infection and always after
receiving rituximab. RT-PCR was positive in the nasopharyngeal swab and also in plasma.
Patients were treated during flares with remdesivir, hyperimmune plasma, and
corticosteroids. These two cases showed the unresolved problem of COVID-19 in
immunosuppressant patients and showed that despite the vast amount of information
available on SARS-CoV-2, information in this subgroup of patients is lacking. | es |
dc.format | application/pdf | es |
dc.format.extent | 7 p. | es |
dc.language.iso | eng | es |
dc.publisher | Frontiers Media S.A. | es |
dc.relation.ispartof | Frontiers in Immunology, 13, 1-7. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | SARS-CoV-2 | es |
dc.subject | COVID-19 | es |
dc.subject | Immunocompromised | es |
dc.subject | Anti-CD20 | es |
dc.subject | Rituximab | es |
dc.subject | Lymphoma | es |
dc.subject | Case report | es |
dc.title | Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Patients With Complete Remission B-Cell Lymphoma and Anti-CD20 Monoclonal Antibody Therapy: A Case Report of Two Cases | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://www.frontiersin.org/articles/10.3389/fimmu.2022.860891/full | es |
dc.identifier.doi | 10.3389/fimmu.2022.860891 | es |
dc.journaltitle | Frontiers in Immunology | es |
dc.publication.volumen | 13 | es |
dc.publication.initialPage | 1 | es |
dc.publication.endPage | 7 | es |
dc.contributor.funder | Instituto de Salud Carlos III | es |
dc.contributor.funder | Ministerio de Ciencia, Innovación y Universidades (MICINN). España | es |
dc.contributor.funder | Fondo Europeo de Desarrollo Regional | es |